US States Restrict Medicaid Coverage for GLP-1 Weight-Loss Drugs

Several United States cities and states are restricting or eliminating Medicaid coverage for GLP-1 receptor agonist medications used for weight loss. This shift comes as public spending on these drugs, including Ozempic and Wegovy, has increased dramatically due to high demand.

While Medicaid programs are generally required to cover most FDA-approved drugs, a long-standing statutory exception allows states to choose whether to cover medications specifically for weight loss. Coverage remains mandatory for other indications, such as cardiovascular disease, sleep apnea, and type 2 diabetes.

Fiscal Pressures and Budgetary Constraints

The decision to limit coverage is driven by tightening budgets and fiscal uncertainty. State Medicaid programs are currently bracing for federal cuts included in the 2025 reconciliation law, a broad tax and spending law enacted by President Donald Trump.

The financial impact of these medications has been significant. In 2018, national spending on GLP-1 drugs was $13.7 billion; by 2023, that figure rose to $71 billion.

Public payers, including state Medicaid programs and some large employer firms, are now re-evaluating their obesity drug coverage to manage these upfront costs.

Public Health Impact and Obesity Trends

The restriction of these drugs occurs amidst a high prevalence of obesity in the U.S. Population. According to the Centers for Disease Control and Prevention, the adult obesity rate was 40% in August 2023. A Gallup report indicated that the rate fell to 37% in 2025.

The adoption of GLP-1 therapies has grown rapidly. KFF reported that 12% of adults were taking a GLP-1 drug in November 2025, which represented a 6% increase from 18 months prior.

The potential impact on Medicaid recipients is substantial, as almost four in ten adults and one-quarter of children enrolled in Medicaid have obesity.

Medical Perspectives on Long-term Costs

Healthcare providers and legislators argue that the short-term financial savings achieved by dropping coverage may be offset by higher long-term healthcare costs. They suggest that reducing access to obesity treatments will force states to pay for more health complications related to obesity in the future.

Patients should have access to these therapies. It’s just very challenging right now for payers to be able to afford covering these medications for everyone who could benefit.

Dr Matthew Klebanoff, professor of internal medicine at the Perelman School of Medicine

The current landscape reflects a tension between the recognized clinical effectiveness of GLP-1 drugs in treating obesity and the budgetary limitations of public health programs.